Payment Breakdown by Category
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $28,272 | 11 | 76.0% |
| Consulting Fee | $5,472 | 3 | 14.7% |
| Travel and Lodging | $2,727 | 10 | 7.3% |
| Food and Beverage | $717.89 | 11 | 1.9% |
| Education | $19.25 | 1 | 0.1% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Amgen Inc. | $37,132 | 32 | $0 (2024) |
| MEDAC PHARMA, INC. | $22.33 | 1 | $0 (2018) |
| SOBI, INC | $19.25 | 1 | $0 (2024) |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $18.48 | 1 | $0 (2017) |
| AbbVie, Inc. | $16.86 | 1 | $0 (2017) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $34,998 | 30 | Amgen Inc. ($34,978) |
| 2023 | $2,153 | 3 | Amgen Inc. ($2,153) |
| 2018 | $22.33 | 1 | MEDAC PHARMA, INC. ($22.33) |
| 2017 | $35.34 | 2 | Boehringer Ingelheim Pharmaceuticals, Inc. ($18.48) |
All Payment Transactions
36 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 11/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $156.03 | General |
| Category: Inflammation | ||||||
| 11/14/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $26.59 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,648.00 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,216.00 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $267.90 | General |
| Category: Inflammation | ||||||
| 11/13/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $22.09 | General |
| Category: Inflammation | ||||||
| 11/09/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $242.95 | General |
| Category: Inflammation | ||||||
| 11/08/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $131.04 | General |
| Category: Inflammation | ||||||
| 10/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,648.00 | General |
| Category: Inflammation | ||||||
| 10/17/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,432.00 | General |
| Category: Inflammation | ||||||
| 10/15/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $121.89 | General |
| Category: Inflammation | ||||||
| 10/06/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,040.00 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $477.75 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $258.63 | General |
| Category: Inflammation | ||||||
| 10/01/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | Cash or cash equivalent | $78.85 | General |
| Category: Inflammation | ||||||
| 09/27/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $278.90 | General |
| Category: Inflammation | ||||||
| 09/25/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $185.72 | General |
| Category: Inflammation | ||||||
| 09/03/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,648.00 | General |
| Category: Inflammation | ||||||
| 09/03/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,432.00 | General |
| Category: Inflammation | ||||||
| 08/30/2024 | Amgen Inc. | TAVNEOS (Drug) | Food and Beverage | In-kind items and services | $149.99 | General |
| Category: Inflammation | ||||||
| 08/22/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | In-kind items and services | $713.60 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,648.00 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $608.00 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $137.00 | General |
| Category: Inflammation | ||||||
| 08/20/2024 | Amgen Inc. | TAVNEOS (Drug) | Travel and Lodging | Cash or cash equivalent | $9.00 | General |
| Category: Inflammation | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 13 | 563 | 954 | $246,778 | $72,593 |
| 2022 | 12 | 587 | 1,042 | $250,408 | $78,106 |
| 2021 | 13 | 581 | 957 | $268,161 | $81,889 |
| 2020 | 15 | 598 | 905 | $234,766 | $66,013 |
All Medicare Procedures & Services
53 procedure records from CMS Medicare Utilization — Page 1 of 3
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2023 | 205 | 327 | $119,028 | $34,309 | 28.8% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2023 | 61 | 89 | $43,521 | $14,217 | 32.7% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2023 | 33 | 33 | $23,001 | $6,293 | 27.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2023 | 48 | 62 | $15,314 | $4,650 | 30.4% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2023 | 23 | 23 | $12,742 | $3,262 | 25.6% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 11 | 14 | $9,856 | $2,242 | 22.7% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2023 | 28 | 28 | $2,520 | $2,123 | 84.2% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2023 | 24 | 29 | $8,643 | $2,105 | 24.4% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2023 | 24 | 30 | $5,978 | $1,579 | 26.4% |
| G0008 | Administration of influenza virus vaccine | Office | 2023 | 29 | 29 | $1,885 | $1,077 | 57.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2023 | 14 | 18 | $2,340 | $523.32 | 22.4% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2023 | 47 | 226 | $1,582 | $189.21 | 12.0% |
| J7050 | Infusion, normal saline solution, 250 cc | Office | 2023 | 16 | 46 | $368.00 | $23.29 | 6.3% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 189 | 304 | $107,312 | $34,341 | 32.0% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Office | 2022 | 79 | 107 | $50,825 | $16,998 | 33.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Office | 2022 | 41 | 41 | $27,470 | $8,430 | 30.7% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Office | 2022 | 38 | 38 | $20,444 | $5,532 | 27.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Office | 2022 | 51 | 59 | $14,160 | $4,439 | 31.3% |
| 20610 | Aspiration and/or injection of fluid from large joint | Office | 2022 | 37 | 52 | $12,968 | $3,247 | 25.0% |
| 90694 | Influenza vaccine, quadrivalent inactivated, 0.5 ml dosage | Office | 2022 | 19 | 19 | $1,596 | $1,335 | 83.6% |
| 20600 | Aspiration and/or injection of fluid from small joint | Office | 2022 | 20 | 29 | $5,452 | $1,284 | 23.6% |
| G0008 | Administration of influenza virus vaccine | Office | 2022 | 22 | 22 | $1,430 | $804.54 | 56.3% |
| 20605 | Aspiration and/or injection of fluid from medium joint | Office | 2022 | 11 | 15 | $3,591 | $709.43 | 19.8% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Office | 2022 | 22 | 23 | $2,829 | $686.32 | 24.3% |
| J3301 | Injection, triamcinolone acetonide, not otherwise specified, 10 mg | Office | 2022 | 58 | 333 | $2,331 | $299.81 | 12.9% |
About Dr. Robert Su, M.D
Dr. Robert Su, M.D is a Internal Medicine healthcare provider based in Fremont, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 01/13/2010. The National Provider Identifier (NPI) number assigned to this provider is 1932439932.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Robert Su, M.D has received a total of $37,209 in payments from pharmaceutical and medical device companies, with $34,998 received in 2024. These payments were reported across 36 transactions from 5 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($28,272).
As a Medicare-enrolled provider, Su has provided services to 2,329 Medicare beneficiaries, totaling 3,858 services with total Medicare billing of $298,601. Data is available for 4 years (2020–2023), covering 53 distinct procedure/service records.
Practice Information
- Specialty Internal Medicine
- Other Specialties Rheumatology
- Location Fremont, CA
- Active Since 01/13/2010
- Last Updated 05/28/2020
- Taxonomy Code 207R00000X
- Entity Type Individual
- NPI Number 1932439932
Products in Payments
- TAVNEOS (Drug) $36,220
- Rasuvo (Drug) $22.33
- KINERET (Drug) $19.25
- OFEV (Drug) $18.48
- Humira (Biological) $16.86
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Internal Medicine Doctors in Fremont
Dr. Ashit Jain, M.d, M.D
Internal Medicine — Payments: $131,943
Dr. Varun Chawla
Internal Medicine — Payments: $75,053
Dr. Charles Valone, D.o, D.O
Internal Medicine — Payments: $55,834
Dr. Michael Lenoir, Md, MD
Internal Medicine — Payments: $51,051
Daniel Taylor, M.d, M.D
Internal Medicine — Payments: $20,686
Rajiv Ahuja, M.d, M.D
Internal Medicine — Payments: $15,535